Buy One Get One free -Llimited Time Offer X
Ciclesonide + Formoterol + Tiotropium is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Based on research, the following side effects have been observed when Ciclesonide + Formoterol + Tiotropium is used -
Severe
Moderate
Mild
Common
Unknown
Is the use of Ciclesonide + Formoterol + Tiotropium safe for pregnant women?
Pregnant women may experience moderate side effects from Ciclesonide + Formoterol + Tiotropium. It is best to stop taking Ciclesonide + Formoterol + Tiotropium immediately and inform your doctor if you notice any discomfort.
Is the use of Ciclesonide + Formoterol + Tiotropium safe during breastfeeding?
Due to lack of research work on this topic, the side effects of Ciclesonide + Formoterol + Tiotropium for breastfeeding women are not known.
What is the effect of Ciclesonide + Formoterol + Tiotropium on the Kidneys?
Ciclesonide + Formoterol + Tiotropium may have mild side effects on the kidneys.
What is the effect of Ciclesonide + Formoterol + Tiotropium on the Liver?
Ciclesonide + Formoterol + Tiotropium can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Ciclesonide + Formoterol + Tiotropium on the Heart?
Ciclesonide + Formoterol + Tiotropium can have moderate side effects on the heart. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
Ciclesonide + Formoterol + Tiotropium should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Ciclesonide + Formoterol + Tiotropium unless your doctor advises you to do so -
Is this Ciclesonide + Formoterol + Tiotropium habit forming or addictive?
No, you will not get addicted to Ciclesonide + Formoterol + Tiotropium.
Interaction between Food and Ciclesonide + Formoterol + Tiotropium
There isn't any research available on the side effects of taking Ciclesonide + Formoterol + Tiotropium with food.
Interaction between Alcohol and Ciclesonide + Formoterol + Tiotropium
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Ciclesonide + Formoterol + Tiotropium.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Alvesco® (ciclesonide)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 231
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 359-360
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1207
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 117
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Spiriva® HandiHaler® (tiotropium bromide)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Braltus® (tiotropium bromide)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Perforomist® (formoterol fumarate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 224
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 595-596